KAT6A and ovarian carcinoma: However, both KAT6AIDR‐FUS, whose LLPS was rescued by IDR from FUS, and KAT6AC543G/G657E enhanced PARPi resistance in ovarian cancer cells (Figures 1H–J and 4A,B), indicating that KAT6A LLPS, but not its catalytic function, counteracted the effects of PARPi.